Drugs / mRNA-2416
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03323398 | Aug 2017 → Aug 2021 | ovarian cancer | ModernaTX, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-09-17 | ModernaTX, Inc. | Results Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day q4web.com ↗ |
| 2019-01-08 | ModernaTX, Inc. | Regulatory Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives q4web.com ↗
Immuno-Oncology IND amendment submitted to the FDA for a Phase 2 cohort of OX40L (mRNA-2416) to treat advanced ovarian carcinoma |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-17 | ModernaTX, Inc. | Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day q4web.com ↗ |
| 2019-01-08 | ModernaTX, Inc. | Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-2416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03323398 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA Encoding Human OX40L” NCT03323398 ↗ |